Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436240 | 0.80 | TRPA1 (0.45) | TRPA1ALDH1A1HPGDCYP3A4MAPT | |
| SCHEMBL11474389 | 0.80 | ALOX5 (0.44) | TRPA1ALDH1A1HPGDCYP3A4MAPT | |
| SCHEMBL11474120 | 0.80 | TRPA1 (0.41) | TRPA1ALDH1A1HPGDCYP3A4MAPT | |
| SCHEMBL11474391 | 0.80 | ALOX5 (0.44) | TRPA1ALDH1A1HPGDCYP3A4MAPT | |
| SCHEMBL1515895 | 0.80 | MAPT (0.45) | TRPA1ALDH1A1HPGDCYP3A4MAPT | |
| SCHEMBL10722792 | 0.79 | KCNK3 (0.46) | TRPA1ALDH1A1HPGDCYP3A4MAPT | |
| Trimethylammonium SCHEMBL27360406 | 0.78 | TRPA1 (0.46) | TRPA1ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL14052796 | 0.78 | HPGD (0.49) | TRPA1ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL16802098 | 0.77 | HDAC4 (0.43) | TRPA1CYP3A4MAPTGPR52PTK2 | |
| SCHEMBL10727755 | 0.76 | RAB9A (0.40) | TRPA1ALDH1A1SMN1; SMN2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| CN-106957290-B | A kind of fragrance and its is preparing the application in anti-influenza A virus medicament at Carbox amide | 武汉大学 | 2019-04-09 | — | — | CN | disclosed |
| CN-106957290-A | A kind of fragrant Carbox amide and its application in anti-influenza A virus medicament is prepared | 武汉大学 | 2017-07-18 | — | — | CN | disclosed |
| US-8507680-B2 | Production process of a heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120142924-A1 | PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8143407-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-1481978-B1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| CN-101061090-B | Preparation method of alpha, alpha-difluoroamine | HOKKAIDO UNIV NAT UNIVERSITY CORP | 2011-06-15 | — | — | CN | disclosed |
| US-7829741-B2 | Process for producing α, α-difluoroamine | NATIONAL UNIVERSITY CORPORATION (JP) | 2010-11-09 | — | — | US | disclosed |
| EP-2157078-A1 | Fluorine compound and fluorinating agent comprising the compound | Mitsubishi Gas Chemical Company, Inc. (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20060089513-A1 | Fluorine compound and fluorinating agent comprising the compound | HIDAKA TOSHIO | 2006-04-27 | — | — | US | disclosed |
| US-7019173-B2 | Fluorine compound and fluorinating agent comprising the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1422216-A1 | FLUORINE COMPOUND AND FLUORINATING AGENT COMPRISING THE COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040073065-A1 | Fluorine compound and fluorinating agent comprising the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-04-15 | — | — | US | disclosed |
| CN-1249661-A | Hydroximic acid halogenides, method for production and use thereof | BASF AG (DE) | 2000-04-05 | — | — | CN | disclosed |
| US-4410534-A | 3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors | SYNTEX (U.S.A.) INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4344943-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1982-08-17 | — | — | US | disclosed |
| US-4087539-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, SMOOTH MUSCLE RELAXANTS | SYNTEX (U.S.A.) INC. (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142924-A1 | PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | PIN4, NISCH, HLCS | TRPA1 1811/4885ALDH1A1 3952/4885HPGD 3611/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | TRPA1 1369/4885ALDH1A1 3867/4885HPGD 3680/4885 |
| US-20060089513-A1 | Fluorine compound and fluorinating agent comprising the compound | AFF1, AFF2, RER1 | TRPA1 773/4885ALDH1A1 1429/4885HPGD 4000/4885 |
| US-20040073065-A1 | Fluorine compound and fluorinating agent comprising the compound | AFF1, RER1, AFF2 | TRPA1 1246/4885ALDH1A1 1338/4885HPGD 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.